Diabetes major Eris Lifesciences enters India’s insulin market through joint venture with MJ …
Eris, one of India’s leading players in the Oral Diabetes Care segment, will now extend its product offering to insulins and GLP1 agonists.The 70:30 Joint Venture (with Eris holding a 70% stake) will primarily engage in marketing and…